Marinus Pharmaceuticals selects Orsini Specialty Pharmacy as exclusive specialty pharmacy for ZTALMY.

M2 EQUITYBITES-July 29, 2022-Marinus Pharmaceuticals selects Orsini Specialty Pharmacy as exclusive specialty pharmacy for ZTALMY

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Orsini Specialty Pharmacy, a US-based independent specialty pharmacy focused on rare diseases and gene therapies, announced on Thursday that it has been chosen by United States-based Marinus Pharmaceuticals, Inc as the exclusive specialty pharmacy for ZTALMY (ganaxolone).

ZTALMY is the first and only treatment approved specifically for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older.

Mike Fieri, Orsini Specialty Pharmacy founder and chief executive officer, said...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT